Asthma is the most common life-threatening chronic disease in children. Although guidelines exist for the diagnosis and treatment of asthma, treatment of severe, pediatric asthma remains difficult. Limited studies in the pediatric population on new asthma therapies, complex issues with adolescence and adherence, health disparities, and unequal access to guideline-based care complicate the care of children with severe, persistent asthma. The purpose of this review is to provide an overview of asthma, including asthma subtypes, comorbidities, and risk factors, to discuss diagnostic considerations and pitfalls and existing treatments, and then present existing and emerging therapeutic approaches to asthma management. An improved understanding of asthma heterogeneity, clinical characteristics, inflammatory patterns, and pathobiology can help further guide the management of severe asthma in children. More studies are needed in the pediatric population to understand emerging therapeutics application in children. Effective multimodal strategies tailored to individual characteristics and a commitment to address risk factors, modifiers, and health disparities may help reduce the burden of asthma in the USA.
TrivediM, DentonE. Asthma in children and Adults-What are the differences and what can they tell us about asthma?Front Pediatr2019;7:256.doi:10.3389/fped.2019.00256http://www.ncbi.nlm.nih.gov/pubmed/31294006
6.
RosenbergSL, MillerGE, BrehmJM, . Stress and asthma: novel insights on genetic, epigenetic, and immunologic mechanisms. J Allergy Clin Immunol2014;134:1009–15.doi:10.1016/j.jaci.2014.07.005http://www.ncbi.nlm.nih.gov/pubmed/25129683
7.
MillerRL, HoS-M. Environmental epigenetics and asthma: current concepts and call for studies. Am J Respir Crit Care Med2008;177:567–73.doi:10.1164/rccm.200710-1511PPhttp://www.ncbi.nlm.nih.gov/pubmed/18187692
8.
SchatzM, ZeigerRS, MosenD, . Improved asthma outcomes from allergy specialist care: a population-based cross-sectional analysis. J Allergy Clin Immunol2005;116:1307–13.doi:10.1016/j.jaci.2005.09.027http://www.ncbi.nlm.nih.gov/pubmed/16337464
9.
DietteGB, SkinnerEA, NguyenTT, . Comparison of quality of care by specialist and generalist physicians as usual source of asthma care for children. Pediatrics2001;108:432–7.doi:10.1542/peds.108.2.432http://www.ncbi.nlm.nih.gov/pubmed/11483811
10.
ButzAM, KubJ, BellinMH, . Challenges in providing preventive care to inner-city children with asthma. Nurs Clin North Am2013;48:241–57.doi:10.1016/j.cnur.2013.01.008http://www.ncbi.nlm.nih.gov/pubmed/23659811
11.
WisniveskyJP, LorenzoJ, Lyn-CookR, . Barriers to adherence to asthma management guidelines among inner-city primary care providers. Ann Allergy Asthma Immunol2008;101:264–70.doi:10.1016/S1081-1206(10)60491-7http://www.ncbi.nlm.nih.gov/pubmed/18814449
12.
FinkelsteinJA, LozanoP, ShulruffR, . Self-Reported physician practices for children with asthma: are national guidelines followed?Pediatrics2000;106:886–96.http://www.ncbi.nlm.nih.gov/pubmed/11044140
13.
DesaiM, OppenheimerJ. Elucidating asthma phenotypes and endotypes: progress towards personalized medicine. Ann Allergy Asthma Immunol2016;116:394–401.doi:10.1016/j.anai.2015.12.024http://www.ncbi.nlm.nih.gov/pubmed/27153739
14.
LötvallJ, AkdisCA, BacharierLB, . Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol2011;127:355–60.doi:10.1016/j.jaci.2010.11.037http://www.ncbi.nlm.nih.gov/pubmed/21281866
15.
MadoreA-M, LapriseC. Immunological and genetic aspects of asthma and allergy. J Asthma Allergy2010;3:107–21.doi:10.2147/JAA.S8970http://www.ncbi.nlm.nih.gov/pubmed/21437045
16.
AnsoteguiIJ, MelioliG, CanonicaGW, . Ige allergy diagnostics and other relevant tests in allergy, a world allergy organization position paper. World Allergy Organ J2020;13:100080. doi:10.1016/j.waojou.2019.100080http://www.ncbi.nlm.nih.gov/pubmed/32128023
17.
PakkaselaJ, IlmarinenP, HonkamäkiJ, . Age-Specific incidence of allergic and non-allergic asthma. BMC Pulm Med2020;20:1–9.doi:10.1186/s12890-019-1040-2
HillDA, SpergelJM. The atopic March: critical evidence and clinical relevance. Ann Allergy Asthma Immunol2018;120:131–7.doi:10.1016/j.anai.2017.10.037http://www.ncbi.nlm.nih.gov/pubmed/29413336
20.
BantzSK, ZhuZ, ZhengT. The atopic March: progression from atopic dermatitis to allergic rhinitis and asthma. J Clin Cell Immunol2014;5:202. doi:10.4172/2155-9899.1000202http://www.ncbi.nlm.nih.gov/pubmed/25419479
NiJ, FriedmanH, BoydBC, . Early antibiotic exposure and development of asthma and allergic rhinitis in childhood. BMC Pediatr2019;19:225. doi:10.1186/s12887-019-1594-4http://www.ncbi.nlm.nih.gov/pubmed/31277618
23.
JacksonDJ, GangnonRE, EvansMD, . Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med2008;178:667–72.doi:10.1164/rccm.200802-309OChttp://www.ncbi.nlm.nih.gov/pubmed/18565953
OkselC, GranellR, HaiderS, . Distinguishing wheezing phenotypes from infancy to adolescence. A pooled analysis of five birth cohorts. Ann Am Thorac Soc2019;16:868–76.doi:10.1513/AnnalsATS.201811-837OChttp://www.ncbi.nlm.nih.gov/pubmed/30888842
26.
MikhailI, GraysonMH. Asthma and viral infections: an intricate relationship. Ann Allergy Asthma Immunol2019;123:352–8.doi:10.1016/j.anai.2019.06.020http://www.ncbi.nlm.nih.gov/pubmed/31276807
27.
LiuL, PanY, ZhuY, . Association between rhinovirus wheezing illness and the development of childhood asthma: a meta-analysis. BMJ Open2017;7:e013034. doi:10.1136/bmjopen-2016-013034http://www.ncbi.nlm.nih.gov/pubmed/28373249
28.
SigursN, BjarnasonR, SigurbergssonF, . Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med2000;161:1501–7.doi:10.1164/ajrccm.161.5.9906076http://www.ncbi.nlm.nih.gov/pubmed/10806145
29.
AminP, LevinL, EpsteinT, . Optimum predictors of childhood asthma: persistent wheeze or the asthma predictive index?J Allergy Clin Immunol Pract2014;2:709–15.doi:10.1016/j.jaip.2014.08.009http://www.ncbi.nlm.nih.gov/pubmed/25439361
30.
BuiDS, LodgeCJ, BurgessJA, . Childhood predictors of lung function trajectories and future COPD risk: a prospective cohort study from the first to the sixth decade of life. Lancet Respir Med2018;6:535–44.doi:10.1016/S2213-2600(18)30100-0http://www.ncbi.nlm.nih.gov/pubmed/29628376
31.
HaldarP, PavordID, ShawDE, . Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med2008;178:218–24.doi:10.1164/rccm.200711-1754OChttp://www.ncbi.nlm.nih.gov/pubmed/18480428
32.
MooreWC, MeyersDA, WenzelSE, . Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med2010;181:315–23.doi:10.1164/rccm.200906-0896OChttp://www.ncbi.nlm.nih.gov/pubmed/19892860
FitzpatrickAM, TeagueWG, MeyersDA, . Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National heart, lung, and blood Institute severe asthma research program. J Allergy Clin Immunol2011;127:382–9.doi:10.1016/j.jaci.2010.11.015
35.
VijayakanthiN, GreallyJM, RastogiD. Pediatric obesity-related asthma: the role of metabolic dysregulation. Pediatrics2016;137:e20150812. doi:10.1542/peds.2015-0812http://www.ncbi.nlm.nih.gov/pubmed/27244776
36.
VisnessCM, LondonSJ, DanielsJL, . Association of childhood obesity with atopic and nonatopic asthma: results from the National health and nutrition examination survey 1999-2006. J Asthma2010;47:822–9.doi:10.3109/02770903.2010.489388http://www.ncbi.nlm.nih.gov/pubmed/20707763
37.
WangF, HeXY, BainesKJ, . Different inflammatory phenotypes in adults and children with acute asthma. Eur Respir J2011;38:567–74.doi:10.1183/09031936.00170110http://www.ncbi.nlm.nih.gov/pubmed/21233265
38.
TaylorSL, LeongLEX, ChooJM, . Inflammatory phenotypes in patients with severe asthma are associated with distinct airway microbiology. J Allergy Clin Immunol2018;141:94–103.doi:10.1016/j.jaci.2017.03.044http://www.ncbi.nlm.nih.gov/pubmed/28479329
39.
WalfordHH, DohertyTA. Diagnosis and management of eosinophilic asthma: a US perspective. J Asthma Allergy2014;7:53–65.doi:10.2147/JAA.S39119http://www.ncbi.nlm.nih.gov/pubmed/24748808
40.
BousquetJ, ChanezP, LacosteJY, . Eosinophilic inflammation in asthma. N Engl J Med1990;323:1033–9.doi:10.1056/NEJM199010113231505http://www.ncbi.nlm.nih.gov/pubmed/2215562
FitzpatrickAM, JacksonDJ, MaugerDT, . Individualized therapy for persistent asthma in young children. J Allergy Clin Immunol2016;138:1608–18.doi:10.1016/j.jaci.2016.09.028http://www.ncbi.nlm.nih.gov/pubmed/27777180
43.
KatzLE, GleichGJ, HartleyBF, . Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. Ann Am Thorac Soc2014;11:531–6.doi:10.1513/AnnalsATS.201310-354OChttp://www.ncbi.nlm.nih.gov/pubmed/24606022
44.
OrtegaH, KatzL, GunsoyN, . Blood eosinophil counts predict treatment response in patients with severe eosinophilic asthma. J Allergy Clin Immunol2015;136:825–6.doi:10.1016/j.jaci.2015.05.039http://www.ncbi.nlm.nih.gov/pubmed/26194540
KuruvillaME, LeeFE-H, LeeGB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol2019;56:219–33.doi:10.1007/s12016-018-8712-1http://www.ncbi.nlm.nih.gov/pubmed/30206782
47.
FallonPG, SchwartzC. The high and lows of type 2 asthma and mouse models. J Allergy Clin Immunol2020;145:496–8.doi:10.1016/j.jaci.2019.11.031http://www.ncbi.nlm.nih.gov/pubmed/31812572
48.
Platts-MillsTA. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med2001;164:S1–5.doi:10.1164/ajrccm.164.supplement_1.2103024http://www.ncbi.nlm.nih.gov/pubmed/11704610
49.
BorishL, ChippsB, DenizY, . Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol2005;95:247–53.doi:10.1016/S1081-1206(10)61221-5http://www.ncbi.nlm.nih.gov/pubmed/16200815
50.
Al-RamliW, PréfontaineD, ChouialiF, . T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol2009;123:1185–7.doi:10.1016/j.jaci.2009.02.024http://www.ncbi.nlm.nih.gov/pubmed/19361847
51.
ChakirJ, ShannonJ, MoletS, . Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression. J Allergy Clin Immunol2003;111:1293–8.doi:10.1067/mai.2003.1557http://www.ncbi.nlm.nih.gov/pubmed/12789232
52.
HedlinG, BushA, Lødrup CarlsenK, . Problematic severe asthma in children, not one problem but many: a GA2LEN initiative. Eur Respir J2010;36:196–201.doi:10.1183/09031936.00104809http://www.ncbi.nlm.nih.gov/pubmed/20595164
53.
GallucciM, CarbonaraP, PacilliAMG, . Use of symptoms scores, spirometry, and other pulmonary function testing for asthma monitoring. Front Pediatr2019;7:54.doi:10.3389/fped.2019.00054http://www.ncbi.nlm.nih.gov/pubmed/30891435
54.
ChhabraSK. Clinical application of spirometry in asthma: why, when and how often?Lung India2015;32:635–7.doi:10.4103/0970-2113.168139http://www.ncbi.nlm.nih.gov/pubmed/26664177
55.
PellegrinoR, ViegiG, BrusascoV, . Interpretative strategies for lung function tests. Eur Respir J2005;26:948–68.doi:10.1183/09031936.05.00035205http://www.ncbi.nlm.nih.gov/pubmed/16264058
56.
National Heart, Lung, and Blood Institute (US). Expert panel report 3: guidelines for the diagnosis and management of asthma, 2007.
CalogeroC, FenuG, LombardiE. Measuring airway obstruction in severe asthma in children. Front Pediatr2018;6:189.doi:10.3389/fped.2018.00189http://www.ncbi.nlm.nih.gov/pubmed/30013960
59.
SirouxV, BoudierA, DolgopoloffM, . Forced midexpiratory flow between 25% and 75% of forced vital capacity is associated with long-term persistence of asthma and poor asthma outcomes. J Allergy Clin Immunol2016;137:1709–16.doi:10.1016/j.jaci.2015.10.029http://www.ncbi.nlm.nih.gov/pubmed/26688518
60.
RaoDR, GaffinJM, BaxiSN, . The utility of forced expiratory flow between 25% and 75% of vital capacity in predicting childhood asthma morbidity and severity. J Asthma2012;49:586–92.doi:10.3109/02770903.2012.690481http://www.ncbi.nlm.nih.gov/pubmed/22742446
61.
DempseyTM, ScanlonPD. Pulmonary function tests for the generalist: a brief review. Mayo Clin Proc2018;93:763–71.doi:10.1016/j.mayocp.2018.04.009http://www.ncbi.nlm.nih.gov/pubmed/29866281
CrapoRO, CasaburiR, CoatesAL, . Guidelines for methacholine and exercise challenge testing-1999. this official statement of the American thoracic Society was adopted by the ats board of directors, July 1999. Am J Respir Crit Care Med2000;161:309–29.doi:10.1164/ajrccm.161.1.ats11-99http://www.ncbi.nlm.nih.gov/pubmed/10619836
64.
CoatesAL, WangerJ, CockcroftDW, . ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J2017;49:1601526. doi:10.1183/13993003.01526-2016http://www.ncbi.nlm.nih.gov/pubmed/28461290
65.
LiB-H, GuanW-J, ZhuZ, . Methacholine bronchial provocation test for assessment of bronchial hyperresponsiveness in preschool children. J Thorac Dis2019;11:4328–36.doi:10.21037/jtd.2019.09.47http://www.ncbi.nlm.nih.gov/pubmed/31737318
66.
DweikRA, BoggsPB, ErzurumSC, . An official ats clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med2011;184:602–15.doi:10.1164/rccm.9120-11SThttp://www.ncbi.nlm.nih.gov/pubmed/21885636
Global strategy for asthma management and prevention, global initiative for asthma (GINA), 2019. Available: http://www.ginasthma.org
69.
UllmannN, MirraV, Di MarcoA, . Asthma: differential diagnosis and comorbidities. Front Pediatr2018;6:276.doi:10.3389/fped.2018.00276http://www.ncbi.nlm.nih.gov/pubmed/30338252
YawnBP. The role of the primary care physician in helping adolescent and adult patients improve asthma control. Mayo Clin Proc2011;86:894–902.doi:10.4065/mcp.2011.0035http://www.ncbi.nlm.nih.gov/pubmed/21878602
75.
ChippsBE, BacharierLB, FarrarJR, . The pediatric asthma yardstick: practical recommendations for a sustained step-up in asthma therapy for children with inadequately controlled asthma. Ann Allergy Asthma Immunol2018;120:e11:559–79. doi:10.1016/j.anai.2018.04.002http://www.ncbi.nlm.nih.gov/pubmed/29653238
76.
ZhangL, ZhangX, ZhengJ, . Co-Morbid psychological dysfunction is associated with a higher risk of asthma exacerbations: a systematic review and meta-analysis. J Thorac Dis2016;8:1257–68.doi:10.21037/jtd.2016.04.68http://www.ncbi.nlm.nih.gov/pubmed/27293845
77.
KriegerJ. Home is where the triggers are: increasing asthma control by improving the home environment. Pediatr Allergy Immunol Pulmonol2010;23:139–45.doi:10.1089/ped.2010.0022http://www.ncbi.nlm.nih.gov/pubmed/22375276
78.
KouriA, KaplanA, BouletL-P, . New evidence-based tool to guide the creation of asthma action plans for adults. Can Fam Physician2019;65:103–6.http://www.ncbi.nlm.nih.gov/pubmed/30765356
79.
HolseyCN, CollinsP, ZahranH. Disparities in asthma care, management, and education among children with asthma. Clin Pulm Med2013;20:172–7.doi:10.1097/CPM.0b013e3182991146http://www.ncbi.nlm.nih.gov/pubmed/27570439
80.
Bryant-StephensT. Asthma disparities in urban environments. J Allergy Clin Immunol2009;123:1199–206.doi:10.1016/j.jaci.2009.04.030http://www.ncbi.nlm.nih.gov/pubmed/19501229
81.
FornoE, CeledonJC. Asthma and ethnic minorities: socioeconomic status and beyond. Curr Opin Allergy Clin Immunol2009;9:154–60.doi:10.1097/ACI.0b013e3283292207http://www.ncbi.nlm.nih.gov/pubmed/19326508
82.
CaninoG, McQuaidEL, RandCS. Addressing asthma health disparities: a multilevel challenge. J Allergy Clin Immunol2009;123:1209–17.doi:10.1016/j.jaci.2009.02.043http://www.ncbi.nlm.nih.gov/pubmed/19447484
NorthridgeJ, RamirezOF, StingoneJA, . The role of housing type and housing quality in urban children with asthma. J Urban Health2010;87:211–24.doi:10.1007/s11524-009-9404-1http://www.ncbi.nlm.nih.gov/pubmed/20063071
85.
PachecoCM, CiaccioCE, NazirN, . Homes of low-income minority families with asthmatic children have increased condition issues. Allergy Asthma Proc2014;35:467–74.doi:10.2500/aap.2014.35.3792http://www.ncbi.nlm.nih.gov/pubmed/25584914
86.
HauptmanM, PhipatanakulW. The school environment and asthma in childhood. Asthma Res Pract2015;1:12.doi:10.1186/s40733-015-0010-6http://www.ncbi.nlm.nih.gov/pubmed/26523228
87.
PermaulP, HoffmanE, FuC, . Allergens in urban schools and homes of children with asthma. Pediatr Allergy Immunol2012;23:543–9.doi:10.1111/j.1399-3038.2012.01327.xhttp://www.ncbi.nlm.nih.gov/pubmed/22672325
88.
SheehanWJ, RangsithienchaiPA, MuilenbergML, . Mouse allergens in urban elementary schools and homes of children with asthma. Ann Allergy Asthma Immunol2009;102:125–30.doi:10.1016/S1081-1206(10)60242-6http://www.ncbi.nlm.nih.gov/pubmed/19230463
89.
BaxiSN, MuilenbergML, RogersCA, . Exposures to molds in school classrooms of children with asthma. Pediatr Allergy Immunol2013;24:697–703.doi:10.1111/pai.12127http://www.ncbi.nlm.nih.gov/pubmed/24112429
90.
McConnellR, IslamT, ShankardassK, . Childhood incident asthma and traffic-related air pollution at home and school. Environ Health Perspect2010;118:1021–6.doi:10.1289/ehp.0901232http://www.ncbi.nlm.nih.gov/pubmed/20371422
PerezL, DeclercqC, IñiguezC, . Chronic burden of near-roadway traffic pollution in 10 European cities (APHEKOM network). Eur Respir J2013;42:594–605.doi:10.1183/09031936.00031112http://www.ncbi.nlm.nih.gov/pubmed/23520318
93.
JerrettM, ShankardassK, BerhaneK, . Traffic-Related air pollution and asthma onset in children: a prospective cohort study with individual exposure measurement. Environ Health Perspect2008;116:1433–8.doi:10.1289/ehp.10968http://www.ncbi.nlm.nih.gov/pubmed/18941591
94.
CarlstenC, DybuncioA, BeckerA, . Traffic-Related air pollution and incident asthma in a high-risk birth cohort. Occup Environ Med2011;68:291–5.doi:10.1136/oem.2010.055152http://www.ncbi.nlm.nih.gov/pubmed/20952556
95.
ClarkNA, DemersPA, KarrCJ, . Effect of early life exposure to air pollution on development of childhood asthma. Environ Health Perspect2010;118:284–90.doi:10.1289/ehp.0900916http://www.ncbi.nlm.nih.gov/pubmed/20123607
96.
O'ConnorGT, NeasL, VaughnB, . Acute respiratory health effects of air pollution on children with asthma in US inner cities. J Allergy Clin Immunol2008;121:1133–9.doi:10.1016/j.jaci.2008.02.020http://www.ncbi.nlm.nih.gov/pubmed/18405952
97.
HussainS, LaumbachR, ColemanJ, . Controlled exposure to diesel exhaust causes increased nitrite in exhaled breath condensate among subjects with asthma. J Occup Environ Med2012;54:1186–91.doi:10.1097/JOM.0b013e31826bb64chttp://www.ncbi.nlm.nih.gov/pubmed/23001278
98.
McCreanorJ, CullinanP, NieuwenhuijsenMJ, . Respiratory effects of exposure to diesel traffic in persons with asthma. N Engl J Med2007;357:2348–58.doi:10.1056/NEJMoa071535http://www.ncbi.nlm.nih.gov/pubmed/18057337
SturmJJ, YeattsK, LoomisD. Effects of tobacco smoke exposure on asthma prevalence and medical care use in North Carolina middle school children. Am J Public Health2004;94:308–13.doi:10.2105/AJPH.94.2.308http://www.ncbi.nlm.nih.gov/pubmed/14759947
101.
SchwartzJ, TimonenKL, PekkanenJ. Respiratory effects of environmental tobacco smoke in a panel study of asthmatic and symptomatic children. Am J Respir Crit Care Med2000;161:802–6.doi:10.1164/ajrccm.161.3.9901002http://www.ncbi.nlm.nih.gov/pubmed/10712325
Fonseca FuentesX, KashyapR, HaysJT, . VpALI-Vaping-related acute lung injury: a new killer around the block. Mayo Clin Proc2019;94:2534–45.doi:10.1016/j.mayocp.2019.10.010http://www.ncbi.nlm.nih.gov/pubmed/31767123
104.
ChungS, BaumlinN, DennisJS, . Electronic cigarette vapor with nicotine causes airway mucociliary dysfunction preferentially via TRPA1 receptors. Am J Respir Crit Care Med2019;200:1134–45.doi:10.1164/rccm.201811-2087OChttp://www.ncbi.nlm.nih.gov/pubmed/31170808
105.
ChaudhuriR, LivingstonE, McMahonAD, . Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am J Respir Crit Care Med2006;174:127–33.doi:10.1164/rccm.200510-1589OChttp://www.ncbi.nlm.nih.gov/pubmed/16645173
106.
Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC), CloutierMM, BaptistAP, . 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol2020;146:1217–70.doi:10.1016/j.jaci.2020.10.003http://www.ncbi.nlm.nih.gov/pubmed/33280709
107.
AhmetA, KimH, SpierS. Adrenal suppression: a practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy. Allergy Asthma Clin Immunol2011;7:13.doi:10.1186/1710-1492-7-13http://www.ncbi.nlm.nih.gov/pubmed/21867553
ChungLP, PatonJY. Two Sides of the Same Coin?-Treatment of Chronic Asthma in Children and Adults. Front Pediatr2019;7:62.doi:10.3389/fped.2019.00062http://www.ncbi.nlm.nih.gov/pubmed/30915319
110.
LemanskeRF, MaugerDT, SorknessCA, . Step-Up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med2010;362:975–85.doi:10.1056/NEJMoa1001278http://www.ncbi.nlm.nih.gov/pubmed/20197425
111.
RamFSF, CatesCJ, DucharmeFM. Long-Acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev2005;1:CD003137. doi:10.1002/14651858.CD003137.pub2http://www.ncbi.nlm.nih.gov/pubmed/15674901
112.
XiaY, KeltonCML, XueL, . Safety of long-acting beta agonists and inhaled corticosteroids in children and adolescents with asthma. Ther Adv Drug Saf2013;4:254–63.doi:10.1177/2042098613504124http://www.ncbi.nlm.nih.gov/pubmed/25114786
SuissaS, IsraelE, DonohueJ, . Food and drug Administration–mandated trials of long-acting β-Agonist safety in asthma. bang for the buck?Am J Respir Crit Care Med2018;197:987–90.doi:10.1164/rccm.201709-1940PP
AverellCM, StanfordRH, LalibertéF, . Medication adherence in patients with asthma using once-daily versus twice-daily ICS/LABAs. J Asthma2021;58:102–11.doi:10.1080/02770903.2019.1663429http://www.ncbi.nlm.nih.gov/pubmed/31607180
117.
SobierajDM, WeedaER, NguyenE, . Association of inhaled corticosteroids and long-acting β-Agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. JAMA2018;319:1485–96.doi:10.1001/jama.2018.2769http://www.ncbi.nlm.nih.gov/pubmed/29554195
118.
CatesCJ, LassersonTJ. Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev2009:CD007313. doi:10.1002/14651858.CD007313.pub2http://www.ncbi.nlm.nih.gov/pubmed/19370682
119.
CatesCJ, KarnerC. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev2013:CD007313. doi:10.1002/14651858.CD007313.pub3http://www.ncbi.nlm.nih.gov/pubmed/23633340
120.
BeasleyR, HollidayM, ReddelHK, . Controlled trial of Budesonide-Formoterol as needed for mild asthma. N Engl J Med2019;380:2020–30.doi:10.1056/NEJMoa1901963http://www.ncbi.nlm.nih.gov/pubmed/31112386
GuevaraJP, DucharmeFM, KerenR, . Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma. Cochrane Database Syst Rev2006:CD003558. doi:10.1002/14651858.CD003558.pub2http://www.ncbi.nlm.nih.gov/pubmed/16625584
123.
Childhood Asthma Management Program Research Group, SzeflerS, WeissS, . Long-Term effects of budesonide or nedocromil in children with asthma. N Engl J Med2000;343:1054–63.doi:10.1056/NEJM200010123431501http://www.ncbi.nlm.nih.gov/pubmed/11027739
AalbersR, ParkHS. Positioning of long-acting muscarinic antagonists in the management of asthma. Allergy Asthma Immunol Res2017;9:386–93.doi:10.4168/aair.2017.9.5.386http://www.ncbi.nlm.nih.gov/pubmed/28677351
127.
HamelmannE. Long-acting muscarinic antagonists for the treatment of asthma in children-a new kid in town. Allergo J Int2018;27:220–7.doi:10.1007/s40629-018-0066-yhttp://www.ncbi.nlm.nih.gov/pubmed/30416934
128.
BuhlR, FitzGeraldJM, BusseWW. Tiotropium add-on to inhaled corticosteroids versus addition of long-acting β2-agonists for adults with asthma. Respir Med2018;143:82–90.doi:10.1016/j.rmed.2018.08.014http://www.ncbi.nlm.nih.gov/pubmed/30261998
129.
ChauhanBF, DucharmeFM. Anti-Leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev2012:CD002314. doi:10.1002/14651858.CD002314.pub3http://www.ncbi.nlm.nih.gov/pubmed/22592685
130.
ChauhanBF, DucharmeFM. Addition to inhaled corticosteroids of long-acting beta-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database of Syst Rev2014:CD003137.
131.
ScaparrottaA, Di PilloS, AttanasiM, . Montelukast versus inhaled corticosteroids in the management of pediatric mild persistent asthma. Multidiscip Respir Med2012;7:13. doi:10.1186/2049-6958-7-13http://www.ncbi.nlm.nih.gov/pubmed/22958412
HewM, ChungKF. Corticosteroid insensitivity in severe asthma: significance, mechanisms and aetiology. Intern Med J2010;40:323–34.doi:10.1111/j.1445-5994.2010.02192.xhttp://www.ncbi.nlm.nih.gov/pubmed/20180872
134.
LiuD, AhmetA, WardL, . A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol2013;9:30.doi:10.1186/1710-1492-9-30http://www.ncbi.nlm.nih.gov/pubmed/23947590
135.
VanfleterenL, FabbriLM, PapiA, . Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. Int J Chron Obstruct Pulmon Dis2018;13:3971–81.doi:10.2147/COPD.S185975http://www.ncbi.nlm.nih.gov/pubmed/30587953
136.
VirchowJC, KunaP, PaggiaroP, . Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and trigger): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet2019;394:1737–49.doi:10.1016/S0140-6736(19)32215-9http://www.ncbi.nlm.nih.gov/pubmed/31582314
137.
GibsonPG, YangIA, UphamJW, . Efficacy of azithromycin in severe asthma from the AMAZES randomised trial. ERJ Open Res2019;5:00056-2019–2019.doi:10.1183/23120541.00056-2019http://www.ncbi.nlm.nih.gov/pubmed/31886156
138.
RaissyHH, BlakeK. Macrolides for acute wheezing episodes in preschool children. Pediatr Allergy Immunol Pulmonol2016;29:100–3.doi:10.1089/ped.2016.0663http://www.ncbi.nlm.nih.gov/pubmed/27458539
ToscaMA, LicariA, OlceseR, . Immunotherapy and asthma in children. Front Pediatr2018;6:23.doi:10.3389/fped.2018.00231
141.
RameshM, KaragicM. New modalities of allergen immunotherapy. Hum Vaccin Immunother2018;14:2848–63.doi:10.1080/21645515.2018.1502126http://www.ncbi.nlm.nih.gov/pubmed/30183485
142.
LarchéM. Mechanisms of peptide immunotherapy in allergic airways disease. Ann Am Thorac Soc2014;11 Suppl 5:S292–6.doi:10.1513/AnnalsATS.201402-090AWhttp://www.ncbi.nlm.nih.gov/pubmed/25525735
DhamiS, KakourouA, AsamoahF, . Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis. Allergy2017;72:1825–48.doi:10.1111/all.13208http://www.ncbi.nlm.nih.gov/pubmed/28543086
145.
RiceJL, DietteGB, Suarez-CuervoC, . Allergen-Specific immunotherapy in the treatment of pediatric asthma: a systematic review. Pediatrics2018;141:pii: e20173833. doi:10.1542/peds.2017-3833http://www.ncbi.nlm.nih.gov/pubmed/29572287
PenagosM, CompalatiE, TarantiniF, . Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol2006;97:141–8.doi:10.1016/S1081-1206(10)60004-Xhttp://www.ncbi.nlm.nih.gov/pubmed/16937742
148.
OzdemirC, YaziD, GocmenI, . Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma. Pediatr Allergy Immunol2007;18:508–15.doi:10.1111/j.1399-3038.2007.00549.xhttp://www.ncbi.nlm.nih.gov/pubmed/17680909
ZhangW, LinC, SampathV, . Impact of allergen immunotherapy in allergic asthma. Immunotherapy2018;10:579–93.doi:10.2217/imt-2017-0138http://www.ncbi.nlm.nih.gov/pubmed/29569506
151.
BergerW, GuptaN, McAlaryM, . Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol2003;91:182–8.doi:10.1016/S1081-1206(10)62175-8http://www.ncbi.nlm.nih.gov/pubmed/12952113
152.
NormansellR, WalkerS, MilanSJ, . Omalizumab for asthma in adults and children. Cochrane Database Syst Rev2014;49:CD003559.doi:10.1002/14651858.CD003559.pub4
153.
MilgromH, BergerW, NayakA, . Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics2001;108:E36. doi:10.1542/peds.108.2.e36http://www.ncbi.nlm.nih.gov/pubmed/11483846
154.
PaganinF, MangiapanG, ProustA, . Lung function parameters in omalizumab Responder patients: an interesting tool?Allergy2017;72:1953–61.doi:10.1111/all.13202http://www.ncbi.nlm.nih.gov/pubmed/28517027
155.
ChippsBE, LanierB, MilgromH, . Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience. J Allergy Clin Immunol2017;139:1431–44.doi:10.1016/j.jaci.2017.03.002http://www.ncbi.nlm.nih.gov/pubmed/28477722
BelEH, WenzelSE, ThompsonPJ, . Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med2014;371:1189–97.doi:10.1056/NEJMoa1403291http://www.ncbi.nlm.nih.gov/pubmed/25199060
158.
AlbersFC, PriceRG, SmithSG, . Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. J Allergy Clin Immunol2017;140:1464–6.doi:10.1016/j.jaci.2017.06.010http://www.ncbi.nlm.nih.gov/pubmed/28687231
159.
BjermerL, LemiereC, MasperoJ, . Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest2016;150:789–98.doi:10.1016/j.chest.2016.03.032http://www.ncbi.nlm.nih.gov/pubmed/27056586
160.
FitzGeraldJM, BleeckerER, BourdinA, . Two-Year integrated efficacy and safety analysis of Benralizumab in severe asthma. J Asthma Allergy2019;12:401–13.doi:10.2147/JAA.S227170http://www.ncbi.nlm.nih.gov/pubmed/31849500
161.
BleeckerER, FitzGeraldJM, ChanezP, . Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet2016;388:2115–27.doi:10.1016/S0140-6736(16)31324-1http://www.ncbi.nlm.nih.gov/pubmed/27609408
162.
FitzGeraldJM, BleeckerER, NairP, . Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet2016;388:2128–41.doi:10.1016/S0140-6736(16)31322-8http://www.ncbi.nlm.nih.gov/pubmed/27609406
163.
NairP, WenzelS, RabeKF, . Oral glucocorticoid-sparing effect of Benralizumab in severe asthma. N Engl J Med2017;376:2448–58.doi:10.1056/NEJMoa1703501http://www.ncbi.nlm.nih.gov/pubmed/28530840
164.
BrooksGD. Updated evaluation of Dupilumab in the treatment of asthma: patient selection and reported outcomes. Ther Clin Risk Manag2020;16:181–7.doi:10.2147/TCRM.S192392http://www.ncbi.nlm.nih.gov/pubmed/32184610
165.
CorrenJ, CastroM, O'RiordanT, . Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. J Allergy Clin Immunol Pract2020;8:516–26.doi:10.1016/j.jaip.2019.08.050http://www.ncbi.nlm.nih.gov/pubmed/31521831
166.
RabeKF, NairP, BrusselleG, . Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med2018;378:2475–85.doi:10.1056/NEJMoa1804093http://www.ncbi.nlm.nih.gov/pubmed/29782224
167.
WenzelS, CastroM, CorrenJ, . Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2B dose-ranging trial. Lancet2016;388:31–44.doi:10.1016/S0140-6736(16)30307-5http://www.ncbi.nlm.nih.gov/pubmed/27130691
168.
LaxmananB, HogarthDK. Bronchial thermoplasty in asthma: current perspectives. J Asthma Allergy2015;8:39–49.doi:10.2147/JAA.S49306http://www.ncbi.nlm.nih.gov/pubmed/26028976
169.
BontaPI, ChanezP, AnnemaJT, . Bronchial thermoplasty in severe asthma: best practice recommendations from an expert panel. Respiration2018;95:289–300.doi:10.1159/000488291http://www.ncbi.nlm.nih.gov/pubmed/29669351
170.
ChungKF, WenzelSE, BrozekJL, . International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J2014;43:343–73.doi:10.1183/09031936.00202013http://www.ncbi.nlm.nih.gov/pubmed/24337046
171.
RochmanY, LeonardWJ. Thymic stromal lymphopoietin: a new cytokine in asthma. Curr Opin Pharmacol2008;8:249–54.doi:10.1016/j.coph.2008.03.002http://www.ncbi.nlm.nih.gov/pubmed/18450510
172.
LiY, WangW, LvZ, . Elevated expression of IL-33 and TSLP in the airways of human asthmatics in vivo: a potential biomarker of severe refractory disease. J Immunol2018;200:2253–62.doi:10.4049/jimmunol.1701455http://www.ncbi.nlm.nih.gov/pubmed/29453280
173.
GauvreauGM, O'ByrnePM, BouletL-P, . Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med2014;370:2102–10.doi:10.1056/NEJMoa1402895http://www.ncbi.nlm.nih.gov/pubmed/24846652
174.
SimpsonEL, ParnesJR, SheD. Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2A clinical trial. J Am Acad Dermatol2019;80:1013–21.
FloydH, NiJ, CornishAL, . Siglec-8. A novel eosinophil-specific member of the immunoglobulin superfamily. J Biol Chem2000;275:861–6.doi:10.1074/jbc.275.2.861http://www.ncbi.nlm.nih.gov/pubmed/10625619
177.
ChenZ, BaiF-F, HanL, . Targeting neutrophils in severe asthma via Siglec-9. Int Arch Allergy Immunol2018;175:5–15.doi:10.1159/000484873http://www.ncbi.nlm.nih.gov/pubmed/29306942
178.
DomingoC, PalomaresO, SandhamDA, . The prostaglandin D2 receptor 2 pathway in asthma: a key player in airway inflammation. Respir Res2018;19:189. doi:10.1186/s12931-018-0893-xhttp://www.ncbi.nlm.nih.gov/pubmed/30268119
179.
BrightlingCE, BrusselleG, AltmanP. The impact of the prostaglandin D2 receptor 2 and its downstream effects on the pathophysiology of asthma. Allergy2020;75:761–8.doi:10.1111/all.14001http://www.ncbi.nlm.nih.gov/pubmed/31355946
180.
BatemanED, GuerrerosAG, BrockhausF, . Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids. Eur Respir J2017;50:pii: 1700670:1700670. doi:10.1183/13993003.00670-2017http://www.ncbi.nlm.nih.gov/pubmed/28838980
181.
Ortiz-AlvarezO, MikrogianakisA, SocietyCP, Canadian Paediatric Society, Acute Care Committee. Managing the paediatric patient with an acute asthma exacerbation. Paediatr Child Health2012;17:251–5.doi:10.1093/pch/17.5.251http://www.ncbi.nlm.nih.gov/pubmed/23633900
182.
NievasIFF, AnandKJS. Severe acute asthma exacerbation in children: a stepwise approach for escalating therapy in a pediatric intensive care unit. J Pediatr Pharmacol Ther2013;18:88–104.doi:10.5863/1551-6776-18.2.88http://www.ncbi.nlm.nih.gov/pubmed/23798903
183.
PowellC, Kolamunnage-DonaR, LoweJ. Magnesium sulphate in acute severe asthma in children (MAGNETIC): a randomised, placebo-controlled trial [published correction appears in Lancet Respir Med. 2013 Jun;1(4):285]. Lancet Respir Med2013;1:301–8.
184.
MohammedS, GoodacreS. Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta-analysis. Emerg Med J2007;24:823–30.doi:10.1136/emj.2007.052050http://www.ncbi.nlm.nih.gov/pubmed/18029512
185.
SinghiS, GroverS, BansalA, . Randomised comparison of intravenous magnesium sulphate, terbutaline and aminophylline for children with acute severe asthma. Acta Paediatr2014;103:1301–6.doi:10.1111/apa.12780http://www.ncbi.nlm.nih.gov/pubmed/25164315
186.
GriffithsB, KewKM. Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database Syst Rev2016;4:CD011050. doi:10.1002/14651858.CD011050.pub2http://www.ncbi.nlm.nih.gov/pubmed/27126744
187.
KambalapalliM, NichaniS, UpadhyayulaS. Safety of intravenous terbutaline in acute severe asthma: a retrospective study. Acta Paediatr2005;94:1214–7.doi:10.1111/j.1651-2227.2005.tb02077.xhttp://www.ncbi.nlm.nih.gov/pubmed/16203672
188.
StephanopoulosDE, MongeR, SchellKH, . Continuous intravenous terbutaline for pediatric status asthmaticus. Crit Care Med1998;26:1744–8.doi:10.1097/00003246-199810000-00033http://www.ncbi.nlm.nih.gov/pubmed/9781734
189.
DoymazS, SchneiderJ, SagyM. Early administration of terbutaline in severe pediatric asthma may reduce incidence of acute respiratory failure. Ann Allergy Asthma Immunol2014;112:207–10.doi:10.1016/j.anai.2014.01.003http://www.ncbi.nlm.nih.gov/pubmed/24468309
190.
KangC-M, WuE-T, WangC-C, . Bilevel positive airway pressure ventilation efficiently improves respiratory distress in initial hours treating children with severe asthma exacerbation. J Formos Med Assoc2020;119:1415–21.doi:10.1016/j.jfma.2019.11.013http://www.ncbi.nlm.nih.gov/pubmed/31806384
191.
KorangSK, FeinbergJ, WetterslevJ, . Non-Invasive positive pressure ventilation for acute asthma in children. Cochrane Database Syst Rev2016;9:CD012067. doi:10.1002/14651858.CD012067.pub2http://www.ncbi.nlm.nih.gov/pubmed/27687114
192.
SabatoK, HansonJH. Mechanical ventilation for children with status asthmaticus. Respir Care Clin N Am2000;6:171–88.doi:10.1016/S1078-5337(05)70063-0http://www.ncbi.nlm.nih.gov/pubmed/10639562
193.
SarnaikAP, DaphtaryKM, MeertKL, . Pressure-Controlled ventilation in children with severe status asthmaticus. Pediatr Crit Care Med2004;5:133–8.doi:10.1097/01.PCC.0000112374.68746.E8http://www.ncbi.nlm.nih.gov/pubmed/14987342
194.
EakinMN, RandCS. Improving patient adherence with asthma self-management practices: what works?Ann Allergy Asthma Immunol2012;109:90–2.doi:10.1016/j.anai.2012.06.009http://www.ncbi.nlm.nih.gov/pubmed/22840247
195.
ZolnierekKBH, DimatteoMR. Physician communication and patient adherence to treatment: a meta-analysis. Med Care2009;47:826–34.doi:10.1097/MLR.0b013e31819a5acchttp://www.ncbi.nlm.nih.gov/pubmed/19584762
196.
WilsonSR, StrubP, BuistAS, . Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med2010;181:566–77.doi:10.1164/rccm.200906-0907OChttp://www.ncbi.nlm.nih.gov/pubmed/20019345
UnniE, GabrielS, ArielyR. A review of the use and effectiveness of digital health technologies in patients with asthma. Ann Allergy Asthma Immunol2018;121:680–91.doi:10.1016/j.anai.2018.10.016http://www.ncbi.nlm.nih.gov/pubmed/30352288
199.
TinschertP, JakobR, BarataF, . The potential of mobile Apps for improving asthma self-management: a review of publicly available and Well-Adopted asthma Apps. JMIR Mhealth Uhealth2017;5:e113. doi:10.2196/mhealth.7177http://www.ncbi.nlm.nih.gov/pubmed/28768606
200.
BlakeyJD, BenderBG, DimaAL, . Digital technologies and adherence in respiratory diseases: the road ahead. Eur Respir J2018;52:1801147. doi:10.1183/13993003.01147-2018http://www.ncbi.nlm.nih.gov/pubmed/30409819
